In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioMarin showed that the Vimizim BLA did not have enough data to prove that clinical and commercial sites are different. That’s not the same as concluding there is no difference between the sites, FDA said.